Prometic Life Scie Company Profile (NASDAQ:PFSCF)

About Prometic Life Scie (NASDAQ:PFSCF)

Prometic Life Scie logo

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PFSCF
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $1.21
  • 200 Day Moving Avg: $1.50
  • 52 Week Range: $0.90 - $2.46
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $12.86 million
  • Price / Sales: N/A
  • Book Value: $0.12 per share
  • Price / Book: 7.54
Profitability:
  • EBIDTA: ($93,780,000.00)
Misc:
  • Average Volume: 40,080 shs.
 

Frequently Asked Questions for Prometic Life Scie (NASDAQ:PFSCF)

What is Prometic Life Scie's stock symbol?

Prometic Life Scie trades on the NASDAQ under the ticker symbol "PFSCF."

When will Prometic Life Scie make its next earnings announcement?

Prometic Life Scie is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for Prometic Life Scie.

Who are some of Prometic Life Scie's key competitors?

How do I buy Prometic Life Scie stock?

Shares of Prometic Life Scie can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Prometic Life Scie's stock price today?

One share of Prometic Life Scie stock can currently be purchased for approximately $0.94.


MarketBeat Community Rating for Prometic Life Scie (NASDAQ PFSCF)
Community Ranking:  1.2 out of 5 (star)
Outperform Votes:  11 (Vote Outperform)
Underperform Votes:  33 (Vote Underperform)
Total Votes:  44
MarketBeat's community ratings are surveys of what our community members think about Prometic Life Scie and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Prometic Life Scie (NASDAQ:PFSCF) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Prometic Life Scie (NASDAQ:PFSCF)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Prometic Life Scie (NASDAQ:PFSCF)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Prometic Life Scie (NASDAQ:PFSCF)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Prometic Life Scie (NASDAQ:PFSCF)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Prometic Life Scie (NASDAQ:PFSCF)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Prometic Life Scie (NASDAQ:PFSCF)
Latest Headlines for Prometic Life Scie (NASDAQ:PFSCF)
Source:
DateHeadline
seekingalpha.com logoWeek In Review: China's Life Science Deals Top $1.4 Billion For Week
seekingalpha.com - August 20 at 11:49 AM
seekingalpha.com logoPrometic Life Sciences: A True Underdog
seekingalpha.com - August 18 at 7:05 AM
seekingalpha.com logoProMetic Life Sciences' (PFSCF) CEO Pierre Laurin on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 16 at 6:44 AM
finance.yahoo.com logoInvestor Network: ProMetic Life Sciences Inc. to Host Earnings Call
finance.yahoo.com - August 16 at 6:44 AM
finance.yahoo.com logoPrometic and Shenzhen Royal Asset Management Close Transaction for Joint Venture and Licensing Rights to PBI-4050, PBI-4547 and PBI-4425 in China
finance.yahoo.com - August 15 at 6:14 AM
finance.yahoo.com logoPrometic Reports 2017 Second Quarter Highlights and Financial Results
finance.yahoo.com - August 15 at 6:14 AM
americanbankingnews.com logoPrometic Life Scie (NASDAQ:PFSCF) Set to Announce Earnings on Monday
www.americanbankingnews.com - August 9 at 11:48 AM
finance.yahoo.com logoPrometic to Report its Second Quarter 2017 Financial Results and to Hold Conference Call / Webcast
finance.yahoo.com - August 9 at 6:21 AM
americanbankingnews.com logoZacks: Prometic Life Scie (PFSCF) Receives Consensus Rating of "" from Analysts
www.americanbankingnews.com - July 19 at 9:56 AM
finance.yahoo.com logoPrometic Announces Positive Long Term Clinical Data on Ryplazym™ in Plasminogen Congenital Deficiency and Provides Regulatory Update
finance.yahoo.com - July 11 at 6:34 AM
americanbankingnews.com logoZacks: Prometic Life Scie (PFSCF) Receives Average Rating of "" from Analysts
www.americanbankingnews.com - June 20 at 9:00 AM
finance.yahoo.com logoETFs with exposure to ProMetic Life Sciences, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 7:48 PM
finance.yahoo.com logoProMetic Life Sciences, Inc. :PFSCF-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 9:43 PM
americanbankingnews.com logoZacks: Prometic Life Scie (PFSCF) Receives Average Recommendation of "" from Brokerages
www.americanbankingnews.com - May 19 at 10:04 AM
finance.yahoo.com logoPrometic reports its 2017 annual and special meeting of shareholders highlights
finance.yahoo.com - May 10 at 7:25 PM
finance.yahoo.com logoPrometic's PBI-4050 Shown to Reduce Liver Damage and Fibrosis in High-Fat Diet Induced Obesity and Metabolic Syndrome Mouse Model
finance.yahoo.com - April 20 at 8:54 AM
nasdaq.com logoARLZ Hands Out Pink Slips, JAZZ On A High Note, STDY On Track, TENX Abuzz
www.nasdaq.com - April 7 at 11:52 AM
seekingalpha.com logoPrometic nabs $9.5M order for affinity resin
seekingalpha.com - April 7 at 11:52 AM
finance.yahoo.com logoProMetic Life Sciences, Inc. breached its 50 day moving average in a Bearish Manner : PFSCF-US : April 4, 2017
finance.yahoo.com - April 7 at 11:52 AM
finance.yahoo.com logoPrometic completes the filing of its plasminogen Biologics License Application ("BLA") with the U.S. FDA
finance.yahoo.com - April 7 at 11:52 AM
finance.yahoo.com logoETFs with exposure to ProMetic Life Sciences, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 11:52 AM
finance.yahoo.com logoPrometic Receives $9.5 Million Purchase Order From Multinational Client
finance.yahoo.com - April 7 at 11:52 AM
seekingalpha.com logoProMetic Life Sciences' (PFSCF) CEO Pierre Laurin on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - April 1 at 11:11 AM
finance.yahoo.com logoPrometic Reports its 2016 Fourth Quarter and Year End Highlights and Financial Results
finance.yahoo.com - March 31 at 12:28 AM
finance.yahoo.com logoPrometic and Shenzhen Royal Asset management (SRAM) to establish a joint venture to develop, manufacture and commercialize PBI-4050, PBI-4547 AND PBI-4425 in China
finance.yahoo.com - March 30 at 7:28 PM
finance.yahoo.com logoPrometic to Report its Fourth Quarter and Year-end 2016 Financial Results and Hold Conference Call / Webcast
finance.yahoo.com - March 23 at 7:41 PM
finance.yahoo.com logoProMetic's PBI-4050 continues to demonstrate early evidence of efficacy following completion of idiopathic pulmonary fibrosis Phase 2 clinical trial
finance.yahoo.com - February 22 at 9:17 AM
finance.yahoo.com logoCalifornia Capital Equity, LLC acquires 44 million ProMetic shares through the exercise of all outstanding warrants
finance.yahoo.com - February 6 at 8:45 AM
finance.yahoo.com logoPROMETIC LIFE SCIENCES INC. Financials
finance.yahoo.com - December 15 at 8:12 PM
finance.yahoo.com logoProMetic responds to false market data report regarding insider selling
finance.yahoo.com - December 9 at 7:08 PM
finance.yahoo.com logoProMetic presents PBI-4050's positive effect on diabetic patients' kidneys at the American Society of Nephrology Annual Meeting
finance.yahoo.com - November 18 at 6:24 PM
finance.yahoo.com logoProMetic's PBI-4050 Demonstrates Early Evidence of Efficacy in its Idiopathic Pulmonary Fibrosis ("IPF") Phase 2 Clinical Trial
finance.yahoo.com - November 17 at 10:45 AM
finance.yahoo.com logoProMetic's PBI-4050 shown to reduce pulmonary hypertension and lung remodeling and to improve right ventricular function in heart failure with reduced ejection fraction ("HFrEF")
finance.yahoo.com - November 14 at 10:54 AM
finance.yahoo.com logoProMetic's plasminogen meets primary and secondary end points in pivotal Phase 2/3 trial
finance.yahoo.com - October 26 at 10:14 AM
finance.yahoo.com logoProMetic's PBI-4050 meets primary and secondary end points in metabolic syndrome and type 2 diabetes Phase 2 clinical trial
finance.yahoo.com - October 20 at 8:04 AM
finance.yahoo.com logoProMetic's PBI-4050 Significantly Reduces Liver Fibrosis in Patients with Alström Syndrome
finance.yahoo.com - October 12 at 12:09 PM
finance.yahoo.com logoProMetic announces the addition of tympanic membrane perforations (TMPs) to its plasminogen's targeted indications
finance.yahoo.com - September 6 at 11:30 AM
finance.yahoo.com logoPrometic completes patients' enrolment in pivotal plasminogen phase 2/3 clinical trial
finance.yahoo.com - August 11 at 10:04 AM
finance.yahoo.com logoProMetic Completes Adult Patients' Enrolment in Pivotal IVIG Phase 3 Clinical Trial
finance.yahoo.com - August 9 at 9:59 AM
finance.yahoo.com logoPrometic to report its second quarter 2016 financial results and hold conference call / webcast
finance.yahoo.com - August 2 at 11:45 AM
finance.yahoo.com logoProMetic's plasminogen granted Fast Track designation by the US FDA
finance.yahoo.com - June 13 at 6:30 AM
finance.yahoo.com logoProMetic to present new data on how PBI-4050 keeps pancreatic beta cells alive at the American Diabetic Association's upcoming annual meeting
finance.yahoo.com - June 9 at 7:00 AM

Social

Chart

Prometic Life Scie (PFSCF) Chart for Wednesday, August, 23, 2017

This page was last updated on 8/23/2017 by MarketBeat.com Staff